Global Disruptive Behavior Disorder Treatment Market, By Type (Conduct Disorder, Intermittent Explosive Disorder, Oppositional Defiant Disorder), Treatment (Social and Emotional Skills Training, Medication Management, Individual Therapy, Comprehensive Evaluation, Family Therapy, Group Therapy, Parenting Modification) – Industry Trends and Forecast to 2030.
Disruptive Behavior Disorder Treatments Market Analysis and Size
The prevalence of disruptive behavior disorder statistics is estimated to be 6.1% percent. Oppositional defiant disorder usually develops before the age of 8 and conduct disorder can occur as early as 5 years old (mainly in boys).Data Bridge Market Research analyses that the disruptive behavior disorder treatment market which was USD 1381.06 million in 2022, will reach USD 2087.57 million by 2030, and is expected to undergo a CAGR of 5.3% during the forecast period of 2023 to 2030. "Oppositional Defiant Disorder" dominates the type segment of the Disruptive Behavior Disorder Treatment market owing to the growing demand for better neurological disorder treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Disruptive Behavior Disorder Treatments Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Type (Conduct Disorder, Intermittent Explosive Disorder, Oppositional Defiant Disorder) and Treatment (Social and Emotional Skills Training, Medication Management, Individual Therapy, Comprehensive Evaluation, Family Therapy, Group Therapy, Parenting Modification)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Lilly (U.S), Pfizer Inc. (U.S), Johnson & Johnson Services, Inc. (U.S), Bionomics (Australia), Highland Ridge Hospital (U.S), Lakeview Health (U.S), Boston Children's Hospital (U.S), Integris Health (U.S), ST. JOHN (U.K), Springwoods Behavioral Health. (Arkansas), Alliance Health Durant (U.S), Midwest Health Center (U.S), Chelsea Therapeutics International, Ltd. (U.S), DURECT CORPORATION (U.S), Jane Phillips Medical Center (U.S), KVC Health System (U.S), Mindsbhumika (India), NYU Langone Hospitals (U.S), Seattle Children's Hospital (U.S)
|
|
Market Opportunities
|
|
Market Definition
Disruptive behavior disorder is a disease that is very frequent among children. It can disrupt a child's day-to-day life. Children with disruptive behavior disorder depict a defiant behavior, exhibiting signs of short-temperedness, aggressiveness, arguments, fighting, stealing, and disobeying authority.
Global Disruptive Behavior Disorder Treatments Market Dynamics
Drivers
- Growing Prevalence of DBD
The market for Disruptive Behavior Disorder Treatments is anticipated to grow significantly over the forecast period due to a number of key factors; the increasing prevalence of DBD among children and adolescents is one of the key drivers for the market. According to the Centers for Disease Control and Prevention (CDC), about 9.4% of children aged 2-17 years in the United States have been diagnosed with ADHD, one of the most common DBD.
- Increasing Government Initiatives
The government's initiatives to improve mental health awareness and provide better access to mental health services are driving the growth of the DBD market. For instance, in 2020, the US government passed the Mental Health Access Improvement Act to improve access to mental health services for children and adolescents.
- Rising Awareness and Diagnosis Rates:
The growing awareness about DBD and its impact on children's social, emotional, and academic lives is driving the demand for effective treatment options. The increasing diagnosis rates of DBD are also contributing to the growth of the market.
Opportunities
- Awareness of Digital Therapeutics
The growing popularity of digital therapeutics, which involve the use of technology-based interventions to treat mental health disorders, presents an opportunity for the DBD treatment market. Digital therapeutics offer a non-pharmacological approach to treatment and can be delivered remotely, which can improve access to treatment options.
- Focus on Early Intervention
The focus on early intervention and prevention of DBD presents an opportunity for the market. Early intervention can improve treatment outcomes and reduce the long-term impact of DBD on the patient's social, emotional, and academic life. This presents an opportunity for the development of new treatment options and the expansion of existing treatment options.
- Personalized medicine:
The development of personalized medicine, which involves tailoring treatment based on the patient's genetic makeup and other individual characteristics, presents an opportunity for the DBD treatment market. Personalized medicine can improve treatment outcomes and reduce the risk of adverse effects.
Restraints/Challenges
The lack of consensus on the diagnosis and treatment of DBD, particularly in children and adolescents, limited insurance coverage for mental health services, including DBD treatment, is a major restraint for the market. Also, the stigma associated with mental illness, shortage of trained mental health professionals and delayed diagnosis are projected to challenge the market in the forecast period of 2023-2030.
This Disruptive Behavior Disorder Treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Disruptive Behavior Disorder Treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In 2020, FDA granted Breakthrough Therapy designation to Alkermes's ALKS 3831, a potential treatment for schizophrenia and bipolar disorder that are associated with DBD.
- In 2019, Ironshore Pharmaceuticals received FDA approval for Jornay PM (methylphenidate) extended-release capsules for the treatment of ADHD which is closely related to DBD.
Global Disruptive Behavior Disorder Treatment Market Scope
The Disruptive Behavior Disorder Treatment market is segmented on the basis of type and treatment. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Conduct Disorder
- Intermittent Explosive Disorder
- Oppositional Defiant Disorder
Treatment
- Social and Emotional Skills Training
- Medication Management
- Individual Therapy
- Comprehensive Evaluation
- Family Therapy
- Group Therapy
- Parenting Modification
Global Disruptive Behavior Disorder Treatment Market Regional Analysis/Insights
The global Disruptive Behavior Disorder Treatment market is analysed and market size insights and trends are provided by country, type and treatment as referenced above.
The countries covered in the Disruptive Behavior Disorder Treatment market report U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the Disruptive Behavior Disorder Treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people with rising neurological disorders.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for neurological disorder treatments and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Disruptive Behavior Disorder Treatment Market Share Analysis
The Disruptive Behavior Disorder Treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Disruptive Behavior Disorder Treatment market.
Some of the major players operating in the Disruptive Behavior Disorder Treatment market are:
- Lilly (U.S)
- Pfizer Inc. (U.S)
- Johnson & Johnson Services, Inc. (U.S)
- Bionomics (Australia)
- Highland Ridge Hospital (U.S)
- Lakeview Health (U.S)
- Boston Children's Hospital (U.S)
- Integris Health (U.S)
- ST. JOHN (U.K)
- Springwoods Behavioral Health. (Arkansas)
- Alliance Health Durant (U.S)
- Midwest Health Center (U.S)
- Chelsea Therapeutics International, Ltd. (U.S)
- DURECT CORPORATION (U.S)
- Jane Phillips Medical Center (U.S)
- KVC Health System (U.S)
- Mindsbhumika (India)
- NYU Langone Hospitals (U.S)
- Seattle Children's Hospital (U.S)
SKU-